Unity Biotechnology is an American startup biotechnology company that develops drugs that target senescent cells.
The company's products in development include UBX 1325, which targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases (in Phase 1 clinical trials for diabetic macular edema as of October 2020). In July 2022, the company reported positive results from its Phase 1 study. They also include UBX 1967, a preclinical product targeting ophthalmologic diseases. Bo...